Literature DB >> 16676064

Local delivery of soluble platelet collagen receptor glycoprotein VI inhibits thrombus formation in vivo.

Andreas Bültmann1, Christian Herdeg, Zhongmin Li, Götz Münch, Christine Baumgartner, Harald Langer, Elisabeth Kremmer, Tobias Geisler, Andreas May, Martin Ungerer, Meinrad Gawaz.   

Abstract

Platelet-mediated thrombus formation at the site of vascular injury is a major trigger for thrombo-ischemic complications after coronary interventions. The platelet collagen receptor glycoprotein VI (GPVI) plays a critical role in the initiation of arterial thrombus formation. Endothelial denudation of the right carotid artery in rabbits was induced through balloon injury. Subsequently, local delivery of soluble, dimeric fusion protein of GPVI (GPVI-Fc) (n = 7) or control Fc (n = 7) at the site of vascular injury was performed with a modified double-balloon drug-delivery catheter. Thrombus area within the injured carotid artery was quantified using a computer-assisted image analysis and was used as index of thrombus formation. The extent of thrombus formation was significantly reduced in GPVI-Fc- compared with control Fc-treated carotid arteries (relative thrombus area, GPVI-Fc vs. Fc: 9.3 +/- 4.2 vs. 2.3 +/- 1.7, p < 0.001). Local delivery of soluble GPVI resulted in reduced thrombus formation after catheter-induced vascular injury. These data suggest a selective pharmacological modulation of GPVI-collagen interactions to be important for controlling onset and progression of pathological arterial thrombosis, predominantly or even exclusively at sites of injured carotid arteries in the absence of systemic platelet therapy.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16676064

Source DB:  PubMed          Journal:  Thromb Haemost        ISSN: 0340-6245            Impact factor:   5.249


  3 in total

1.  Inhibition of Glycoprotein VI Clustering by Collagen as a Mechanism of Inhibiting Collagen-Induced Platelet Responses: The Example of Losartan.

Authors:  Peng Jiang; Stéphane Loyau; Maria Tchitchinadze; Jacques Ropers; Guillaume Jondeau; Martine Jandrot-Perrus
Journal:  PLoS One       Date:  2015-06-08       Impact factor: 3.240

2.  The GPVI-Fc fusion protein Revacept reduces thrombus formation and improves vascular dysfunction in atherosclerosis without any impact on bleeding times.

Authors:  Martin Ungerer; Zhongmin Li; Christine Baumgartner; Silvia Goebel; Jasmin Vogelmann; Hans-Peter Holthoff; Meinrad Gawaz; Götz Münch
Journal:  PLoS One       Date:  2013-08-12       Impact factor: 3.240

Review 3.  Targeting GPVI as a novel antithrombotic strategy.

Authors:  Robert K Andrews; Jane F Arthur; Elizabeth E Gardiner
Journal:  J Blood Med       Date:  2014-05-21
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.